Tuesday, November 25, 2014 9:53:08 PM
I don't know if I have a clear 'top 3' - but there have been regular points in years leading up to the present year - where management has (indeed) been far too optimistic about deadlines.
This past year - my biggest legitimate criticism about NNVC's management has been lack of clear communication on two very general points:
1) What - at least in general terms (approximate days/weeks) - time period does it take to make a QC acceptable batch of any particular 'Cide from start to finish?
A working timeline for making a '200 g' (or any other particular quantity synthesis size) - stated publically - would not seem to be particularly revealing of IP or 'trade secret' information AND would have eliminated a lot of the most recent sets of months criticsm of the company. I know enough to make some educated guesses as to how much time is likely to take to do this, but that's an educated guess with no hard data.
2)When is the Shelton plant expected to come online?
Again - I don't think that a hard timeline (or at least a squishy & hedged one) for when they expect the plant to go online - dependent on any missing equipment pieces of equipment are brought into the facility and online would be too revealing of IP or 'trade secrets' - and would have headed off much potential criticism of the company over the last year or so since the facility construction & refurbishment was iniated.
Beyond these couple of points - each of which would seem to be relatively easy to communicate - most of the rest of what goes on behind closed doors for the company has either been relatively forthcoming (IMO) or could be construed as revealing soemthing "IP" related that shouldn't (yet) be revealed.
Everything else that has been leveled as a criticsm of NNVC or it's principles is trumped up or trivial.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM